'A good 30 per cent of people will still get infected after getting the Covishield vaccine.'
A longer shelf life is critical, given many makers have started manufacturing vaccines and stockpiling them, so as to make them available in the market immediately after approval, reports Sohini Das.
The institute's incubation cell claims the start up mortality rate in the incubators are lowest.
Fabiflu sales have grown by 62 per cent in July. It was launched in June. This drug is being used by doctors for mild-to-moderate Covid patients even if they are in home isolation.
The test was carried out by DRDO against a high-speed unmanned aerial target which was successfully intercepted by the missile.
Ajit Mishra, vice president, Research, Religare Broking, answers your stock market queries.
A key lesson for the pharmaceutical sector in this case is to not downplay the significant impact that regulatory non-compliance can have on operations.
Hetero has priced the injectable drug at Rs 5,400 per 100 mg vial. With More drugmakers in line to launch the drug soon, the prices may see a further erosion.
Industry is gathering scientific data to approach the regulator, DCGI, for a review of the suspension order.
Telecom stocks fell after Mukesh Ambani extended Reliance Jio's free offers till March 2017.
Indian equity markets registered their highest single-day percentage gains since early October.
The biotech company's revenues had fallen to as low as Rs 50 cr.
The progress of the GST Bill in Parliament is also likely to remain in focus
Dilip Shanghvi has never tried to be everything to everybody.
Financials were the top losers while oil shares also declined amid weak crude oil prices.
Ajit Mishra, vice president, Research, Religare Broking, answers your queries.
While companies continue to face regulatory pressure leading to higher costs, they see an uptick from the launch of differentiated and high-margin products
Quite a few large- and mid-cap stocks are yet to recover from the note ban, pharma, banking and rural demand-based industries among laggards.
The broader markets were marginally higher with mid-caps and small-caps gaining 0.1-0.4 per cent on the BSE.
On the sectoral front, rate-sensitive sectors such as Bankex and Auto gained by 1% and 0.7% respectively while BSE Consumer Durables gained 1.4%.
Sharp fall in capital goods production and manufacturing activity also dented sentiments.
The S&P BSE Sensex plunged 301 points to close at 25,490 and the Nifty50 fell 86 points to end at 7,815.
The S&P BSE Sensex ended 46 points lower at 24,824 and Nifty50 settled at 7,555, down by 8 points after hitting intra-day high of 7,600.45.
While there has been no commitment from the government on the procurement of vaccines, initial volumes, or distribution plans, there is a likelihood that the low interest loans may be made available to these players only when the time to scale up manufacturing arises.
The antiviral drug may cost around Rs 55,000 for an 11-dose course, or Rs 5,000 per injection -- much less than the price of imports from Bangladesh, reports Sohini Das.
The Delhi High Court on Friday stayed the ban on some fixed dose combination (FDC) drugs of Glaxo SmithKline, Wockhardt and Laboratories Griffon but said action against their sale could be taken in the absence of valid sale and marketing licence.
A widening probe by US authorities involving top drug companies following complaints of price fixing of generics was a point of worry for the participants, said analysts.
PSU bank shares were the top gainers on hopes of a rate by the RBI on easing consumer inflation
Eight of the 30 companies in the BSE Sensex that shared data reported 99 fatalities in 2016-17 against 86 in the previous year. These lives were lost due to industrial accidents at manufacturing facilities. Fatalities owing to road accidents were excluded from the count.
The 30-share Sensex is up 253 points at 29,263 and the 50-share Nifty has gained 68 points at 8,829.
Besides opposing the suspension of three medicines, the sector has also questioned the process adopted by the government.
'What prevents infection are masks, physical distancing and good ventilation.'
Gains were led by index heavyweights with Reliance Industries contributing the most.
Designed to be a quick reaction missile, it has a strike range of 25 km to 30 km.
A land-attack version of the missile was test-launched from Launch Pad-3 of the Integrated Test Range (ITR). An air force variant was fired from an IAF fighter jet over Bay of Bengal.
US stocks rose more than 1% on Tuesday, with the S&P 500 coming less than 2% below its record peak set last month.
Investment in market leaders with a safety-first approach could yield reasonable returns across sectors.
After a volatile session, Sensex closed the day 563 points lower
India on Monday successfully flight-tested its indigenously developed SMART torpedo system, which DRDO said will be a "game changer" in anti-submarine warfare, marking yet another milestone in strengthening the country's maritime strategic capabilities, defence sources said.
Ajit Mishra, vice president, Research, Religare Broking, answers your queries
© 2026 Rediff.com - Investor Information - Advertise with us - Disclaimer - Privacy Policy - Sitemap - Feedback - About us - Terms of use - Grievances